Apellis Pharmaceuticals (APLS)
(Real Time Quote from BATS)
$40.82 USD
-2.78 (-6.38%)
Updated May 23, 2024 12:30 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Apellis Pharmaceuticals, Inc. [APLS]
Reports for Purchase
Showing records 61 - 80 ( 281 total )
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Plot Thickens in GA Market with Izervay Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syfovre Stregnth in 2Q Overshadowed by Safety Concerns as ASRS Stays in Focus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Live From ASRS Day 2: On the Ground Feedback on Syfovre
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Almost Wish It Was Manufacturing; How Long Will Syfovre Safety Remain In Focus?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Live From ASRS: On the Ground Feedback on Syfovre
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Doc Insights Into ASRS Warning Frame our Near-Term Outlook on Syfovres Launch Trajectory; Adjusting PT Down to $82
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another Beovu Or Just A Hiccup? One Thing''s Clear, Near-Term Clarity Unlikely
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ASRS Warning Creates Uncertainty for Syfovre After Strong Launch
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syfovre Safety Reports Raise Questions, But Vial Count Offers An Offset
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Commercial Biotech Preview: Could 2Q23 Reporting Help Restart a Rally?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Conversation With Apellis Pharmaceuticals Management; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Syfovre Makes A Splash In Inaugural Print [1Q23 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L